Clinical trials: Resectable Esophagogastric Adenocarcinoma
Gastric Adenocarcinoma, Esophagogastric Junction Adenocarcinoma
Perioperative Fruquintinib Combined With Sintilimab and SOX for Locally Advanced Gastric or GEJ Adenocarcinoma
The purpose of this clinical trial is to evaluate whether perioperative fruquintinib combined with sintilimab and SOX is effective in treating locally advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.
- Trial name
- NCT07658872
- Testing
- fruquintinib + sintilimab + SOX, Sinitilimab+SOX
- Volunteers
- 120 people
- Sponsor
- Sichuan University
Stomach Neoplasms, Gastrointestinal Neoplasms
FOLFIRINOX vs FLOT Chemotherapy for Resectable Gastric or Esophagogastric Junction Adenocarcinoma
Patients with resectable adenocarcinoma of the stomach or the esophagogastric junction (II-III type by Siewert) without previous therapy will be treated with one of two chemotherapy combinations before and after surgery.
- Conditions
- Stomach Neoplasms, Gastrointestinal Neoplasms, Docetaxel, Oxaliplatin
- Trial name
- RusGCG-01 (NCT04393584)
- Testing
- Irinotecan, 5-FU, Leucovorin
- Where
- Russia
- Volunteers
- 538 people
- Sponsor
- Blokhin's Russian Cancer Research Center
Stomach Cancer, Gastroesophageal Junction Cancer
FLOT vs. FLOT/Ramucirumab for Perioperative Therapy of Gastric or GEJ Cancer (RAMSES)
Previous studies provide a strong theoretical rationale for the conduct of a randomized study evaluating the efficacy and safety of ramucirumab in combination with FLOT in the perioperative treatment of resectable adenocarcinoma…
- Trial name
- RAMSES/FLOT7 (NCT02661971)
- Testing
- Docetaxel, Oxaliplatin, Calciumfolinat
- Where
- 2 sites in Germany, Italy
- Volunteers
- 180 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Adenocarcinoma of Esophagogastric Junction
Neoadjuvant Immunotherapy and Chemoradiotherapy for Locally Advanced Esophagogastric Junction Adenocarcinoma
The purpose of this study was to evaluate the effect and safety of concurrent PD-1 antibody-based long-term radiotherapy followed by 2 cycles SOX with PD-1 in patients with locally advanced adenocarcinoma of esophagogastric…
- Trial name
- NICLA (NCT05505461)
- Testing
- neoadjuvant Radiation plus SOX and PD-1 antibody
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Peking University People's Hospital
Esophagogastric Adenocarcinoma
Platform Trial Evaluating Treatment of Neoadjuvant Trastuzumab-deruxtecan Containing Combination Therapies for HER2+, Resectable Esophagogastric Adenocarcinoma
The study is a phase Ib/II, prospective, single arm, open label, non-randomized, multi-center platform trial assessing the feasibility and safety of different neoadjuvant trastuzumab-deruxtecan containing combinational treatment…
- Trial name
- NeoART (NCT06731803)
- Testing
- Trastuzumab deruxtecan + 5FU/LV, Trastuzumab deruxtecan + FLO
- Where
- 14 sites in Austria, Germany
- Volunteers
- 36 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest